dedicated to science, medicine, and business
Michael P. Bevilacqua, M.D., Ph.D.
CEO, CSO, Director & Co-Founder
Dr. Bevilacqua is co-founder of Amicrobe. He has more than 30 years experience as a medical scientist, inventor, and business executive. He served on the faculty of the Department of Pathology at Brigham and Women's Hospital and Harvard Medical School, where he led a successful research laboratory and was selected as a PEW Scholar. He was then chosen as a Howard Hughes investigator and joined the faculty at UCSD Medical Center. In 1993, he took his first corporate position as Vice President of Amgen and built a division for inflammatory and immunological diseases. Subsequently, Dr. Bevilacqua has worked with start-up corporations in both therapeutics and diagnostics. His scientific work has led to numerous patents and publications.
Timothy J. Deming, Ph.D.
Head of SAB & Co-Founder
Professor Deming is co-founder of Amicrobe. His pioneering work on controlled synthesis and characterization of amino acid copolymers provided foundational technology for the building of Amicrobe. He has published more than 120 articles and 16 patents. Professor Deming’s research uses innovative chemistry to synthesize and characterize complex biomaterials based on amino acids. He has led research programs at UCSB and served as Chair of the UCLA Bioengineering Department, where he is currently a professor.
Daniel J. Huang
Vice President of Operations
Mr. Huang is a versatile executive with significant experience in data management and operations. At Amicrobe, he has responsibility for laboratory and general operations, including oversight of data and project management. His multidisciplinary experience in business operations and laboratory sciences help drive Amicrobe’s innovative product development efforts.
Joseph S. Solomkin, M.D.
Chief Medical Officer
Joseph Solomkin, M.D., F.A.C.S., F.I.D.S.A., is an international leader in the scientific and clinical understanding of surgical and post-traumatic infections. He is also Professor Emeritus, Department of Surgery, University of Cincinnati College of Medicine, as well as Executive Director, OASIS Global. Dr. Solomkin has co-authored more than 130 articles and 30 book chapters and has served as an outside expert to the WHO and CDC for the development of guidelines on the prevention of surgical site infections.
Doug Looker, Ph.D.
Vice President of Manufacturing
Dr. Looker is an experienced scientist with a background in both large and small molecule manufacturing. He has worked in formulation development and clinical trial supply chain management. In his role, Dr. Looker oversees contract manufacturing of Amicrobe's investigational products
Eric Roche, Ph.D.
Director of Preclinical Development
Dr. Roche is an experienced preclinical R&D manager with a track record of leading successful teams. He has proven technical expertise in diverse scientific fields, including animal modeling, antimicrobials, microbiology, and biofilms. At Amicrobe, he leads our efforts on preclinical development, including nonclinical pharmacology and toxicology.
Board of Directors
Chairman & Co-Founder
Michael Flesch is Chairman & CEO of Community Asset Management, a private investment company focused in real estate, a venture capitalist, and former litigation attorney at Brobeck Phleger & Harrison, representing primarily Fortune 500 companies. He has been a member of the Board of Directors of the UCLA Foundation and a Trustee of Occidental College. He has served on finance and investment committees at both universities. Mr. Flesch is also Founder and Chairman of Bruin Biometrics, an innovative medical device company developing systems that can cost-effectively detect and monitor select medical conditions.
Glen March, M.D.
Dr. March is an Ophthalmologist with training in Neuro-Ophthalmology at Harvard Medical School/Massachusetts Eye & Ear Infirmary, and Orbital and Ophthalmic Plastic Surgery at UCLA/Jules Stein Eye Institute. He co-founded March Vision Care, the first minority owned vision plan in 2001. The company grew to over 7 million members in 26 states and the District of Columbia. He functioned as Chairman and CEO until its sale to United Healthcare in 2016. He is co-principal at Strategem Investments, LLC, a private equity firm focused on early stage funding of innovative ideas. Local community board positions include: the Ahmanson Foundation and the Metropolitan LA YMCA.
Albert Carnesale, Ph.D.
Dr. Carnesale is Chancellor Emeritus and Professor Emeritus at University of California, Los Angeles (UCLA). His research and teaching focus on public policy issues having scientific and technological dimensions. He is the author/co-author of six books and over 100 articles. He has chaired multiple National Academies Committees. He was on the Obama Administration Blue Ribbon Commission on America's Nuclear Future and on the Secretary of Energy's Advisory Board. He is a member of the National Academy of Engineering, Council on Foreign Relations, and Pacific Council on International Policy; and a Fellow of the American Academy of Arts and Sciences and American Association for the Advancement of Science. Prior to UCLA, Dr. Carnesale was at Harvard University as Lucius N. Littauer Professor of Public Policy and Administration, Dean of the John F. Kennedy School of Government, and Provost of Harvard University.
Mr. Burns is CEO of Bruin Biometrics, an innovative medical device company developing systems that can cost-effectively detect and monitor select medical conditions. Appointed CEO in 2012, Martin established and led the successful journey of BBI’s SEM Scanner through FDA de novo Marketing Authorization (2018), CE Marking (2013) and the UK's National Institute of Health and Care Excellence' (NICE) Medical Innovation Briefing process (MIB 182, 2019). Previously, he spent more than 15 years as a management consultant at Deloitte and PricewaterhouseCoopers. Mr. Burns has led corporate strategy, innovation, operations, quality and regulatory, M&A and global expansion assignments for medical device and life sciences companies. Martin earned his BA (1996) at the London School of Economics and Political Science (LSE) and his MBA at UCLA’s Anderson School of Management (2007).
Michael P. Bevilacqua, M.D., Ph.D.
CEO, CSO, Director & Co-Founder
Dr. Bevilacqua is co-founder of Amicrobe and services as Chief Executive Officer and Chief Science Officer. He has more than 30 years experience as a medical scientist, inventor, and business executive. He served on the faculty of the Department of Pathology at Brigham and Women's Hospital and Harvard Medical School, where he led a successful research laboratory and was selected as a PEW Scholar. He was then chosen as a Howard Hughes investigator and joined the faculty at UCSD Medical Center. In 1993, he took his first corporate position as Vice President of Amgen and built a division for inflammatory and immunological diseases. Subsequently, Dr. Bevilacqua has worked with start-up corporations in both therapeutics and diagnostics. His scientific work has led to numerous patents and publications.
Alan C. Mendelson
Secretary and Corporate Counsel
Alan Mendelson retired as a senior partner at Latham & Watkins LLP, effective December 31, 2020. Prior to his retirement, Mr. Mendelson served as co-chair of the firm's Life Sciences Industry Group and his practice was primarily targeted toward emerging and public growth biotechnology and medical device companies. During his approximately 47 years of private firm practice, Mr. Mendelson served as the corporate secretary for many private and public companies and received numerous honors for his service to the life sciences industry. Mr. Mendelson currently serves on the Board of Directors of Coherus BioSciences, Inc., Neuvogen, Inc., Xomics Biopharma, Inc. and BBI Medical Solutions, Inc. He also serves on the Board of Trustees of the UC Berkeley Foundation and the Buck Institute for Research on Aging and on the Board of Directors of the National Kidney Foundation.